Reduction of Low-Density Lipoprotein Cholesterol (LDL-C) With PCSK9 Inhibition in Heterozygous Familial Hypercholesterolemia Disorder Study

Inclusion Criteria: * Male or female ≥ 18 to ≤ 75 years of age * Diagnosis of heterozygous familial hypercholesterolemia by having met the diagnostic criteria outlined by the Simon Broome Register Group (Scientific Steering Committee 1991) * On an approved statin, with or without ezetimibe, with stable dose(s) for at least 4 weeks * Fasting Low-Density Lipoprotein Cholesterol (LDL-C) ≥ 100 mg/dL * Fasting triglycerides ≤ 400 mg/dL Exclusion Criteria: * Homozygous familial hypercholesterolemia * Low-Density Lipoprotein (LDL) or plasma apheresis within 12 months prior to randomization * New York Heart Association (NYHA) III or IV heart failure, or known left ventricular ejection fraction \< 30% * Uncontrolled cardiac arrhythmia * Myocardial infarction, unstable angina, percutaneous coronary intervention (PCI), coronary artery bypass graft (CABG) or stroke within 3 months prior to randomization * Type 1 diabetes; newly diagnosed or poorly controlled type 2 diabetes (HbA1c \> 8.5%) * Uncontrolled hypertension